Zhejiang Provincial Key Lab for Cardiovascular Diseases Diagnosis and Treatment
Zhejiang Provincial Key Lab of Cardiovascular Disease Diagnosis and Treatment was established in December 2009. The main lab is located at SAHZU. Currently, under the leadership of Prof. Wang Jian’an, the lab has 26 research staffs, including 12 faculty members (professors of all ranks), 4 lecturers and 10 technical instructors.
The lab’s main research areas include:
(1) stem cell therapy for heart failure;
(2) the basic and clinical study of heart valve disease;
(3) early diagnosis and intensive intervention of coronary heart disease;
(4) basic and translational study of heart failure.
At the present, the lab is well funded by a variety of funds, such as the National Basic Research Program of China (973), the National High-Tech R&D Program of China (863), the Major National R&D Project, the National Science and Technology Support Program and the Program Research Grants from the National Natural Science Foundation. The amount of all the funds is over CNY 60 million.
Within the past five years, more than 60 peer-reviewed research papers have been published, some of which are published in prestigious journals in the field of biomedical sciences and cardiovascular biology, such as Journal of Clinical Investigation, Circulation Research, Stem Cells, Journal of Interventional Cardiology, etc.
In the past few years, the lab has made contributions to the development of cardiovascular disease therapy. They have won several scientific awards, including the second prize of National Science and Technology Progress, the first prize of Science and Technology Award of Zhejiang Province twice. Dr. Jian’an Wang, the director of the lab, won Bethune Medal in 2012, Zhejiang Province Science and Technology Significant Contribution Award in 2015 and Wu Jieping Innovation Award in 2015.
Zhejiang Provincial Key Lab for Prevention and Treatment of Main Blinding Eye Diseases
Eye Diseases Leading to Blindness is one of the important diseases influencing public health, and improving the prevention and treatment of these diseases is in line with the requirements of the social and economic development and technology development.
According to the World Health Organization statistics, China is one of the countries with the highest number of blind people in the world. China now has about 13,000,000 blind people, with an annual growth of 800,000. To curb this trend and ensure the sustainable development of people's health and national economy, it is imperative to prevent and treat main blinding eye diseases. The establishment of this lab aims to strengthen the interdisciplinary cooperation and research in the fields of ophthalmology, materials science and bio-engineering, make patent eligible products for treating blinding eye diseases, and better meet the health needs of the people.
Research Focuses include:
• study the related genes and gene polymorphism of important eye diseases leading to blindness;
• independently research and develop new ophthalmic implants for the prevention and treatment of eye diseases leading to blindness;
• study the quality control and key technique standard of eye diseases leading to blindness.
It is expected to reveal the genetic basis of congenital and developmental eye diseases (such as congenital cataract) or genetic eye diseases (such as age-related macular degeneration, glaucoma, etc.), make new intraocular implants with independent intellectual property rights which can meet the ophthalmology application requirements in terms of surface morphology, physicochemical properties, drug sustained release rate and time of duration, and establish the standard of key techniques of treating eye diseases leading to blindness and applicable to the training of ophthalmologic surgeons at the grass-roots level.